悪性胸水の世界市場レポート 2025年

悪性胸水市場規模は、今後数年間で力強い成長が見込まれます。2029年には61億7,000万米ドルに成長し、CAGRは6.8%となります。予測期間中の成長は、ヘルスケアインフラの拡大、政府支援の増加、がんサバイバーの増加、在宅ケアの需要拡大、リキッドバイオプシーの進歩などに起因すると考えられます。この期間の主な動向としては、イメージングツールにおける人工知能の統合、標的がん治療の進展、胸膜癒着術の進歩、バイオマーカーの改善、新規治療薬の臨床試験の拡大などが挙げられます。

肺がん患者数の増加が悪性胸水市場の成長を牽引すると予想されます。肺がんは、肺における異常細胞の制御不能な増殖を特徴とする疾患であり、腫瘍を形成したり、正常な肺機能を破壊したりします。タバコに含まれる有害な化学物質に長期間さらされると、肺組織にダメージを与え、遺伝子変異を引き起こし、がん細胞の無秩序な増殖を促すため、肺がんを発症するリスクが大幅に高まる。悪性胸水は、胸膜腔内での腫瘍の広がりを助長することにより、進行した肺がんの進行を知らせ、呼吸機能を悪化させ、予後を悪くします。例えば、2023年1月、米国を拠点とする専門機関である米国がん協会は、2022年の肺がんおよび気管支がんの新規症例数は推定236,740例、推定死亡数は130,180例であったと報告しました。2023年については、新規症例数は23万8,340人に増加し、死亡者数は12万7,070人とわずかに減少すると予想されています。こうした肺がん患者の増加が、悪性胸水市場の成長を牽引しています。

ヘルスケアインフラの改善は、悪性胸水市場の成長をさらに促進すると予測されています。ヘルスケアインフラには、病院、診療所、医療機器、ITシステム、医療従事者など、ヘルスケアサービスを提供するために必要な物理的、技術的、組織的要素が含まれます。ヘルスケアインフラの強化は、より良い疾病管理の必要性によって推進され、アクセシビリティ、効率性、ケアの質の向上を目指しています。高度な医療技術、設備の整った医療施設、専門的なケアへのアクセスを可能にすることで、より良い診断、治療、悪性胸水の管理をサポートし、最終的には患者の転帰の改善につながります。例えば、2023年5月、米国の非営利団体である米国ヘルスケア協会は、米国の病院数が前年の6,093から6,129へと0.591％増加したと報告しました。このようなヘルスケアインフラの向上が、悪性胸水市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の悪性胸水PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の悪性胸水市場：成長率分析
• 世界の悪性胸水市場の実績：規模と成長、2019年～2024年
• 世界の悪性胸水市場の予測：規模と成長、2024年～2029年、2034年
• 世界の悪性胸水総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の悪性胸水市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 全身療法
• 治療的胸腔穿刺
• 胸腔ドレナージと胸膜癒着術
• 留置胸膜カテーテル
• 世界の悪性胸水市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 胸水細胞診
• 免疫組織化学検査
• 画像検査
• 胸膜胸郭症
• 胸膜鏡検査
• 胸膜生検
• 世界の悪性胸水市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 外来診療所
• その他のエンドユーザー
• 世界の悪性胸水市場、全身療法のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 化学療法
• 標的療法
• 免疫療法
• 世界の悪性胸水市場、治療的胸腔穿刺のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 単回胸腔穿刺
• 胸腔穿刺の繰り返し
• 世界の悪性胸水市場、胸腔ドレナージと胸膜癒着術の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 化学的胸膜癒着術
• 機械的胸膜癒着術
• 生物学的胸膜癒着術
• 世界の悪性胸水市場、留置胸膜カテーテルの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• トンネル型胸膜カテーテル
• 非トンネル型胸膜カテーテル

第7章 地域別・国別分析

• 世界の悪性胸水市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の悪性胸水市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 悪性胸水市場：競合情勢
• 悪性胸水市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Medline Industries LP
• Becton Dickinson and Company
• Cook Medical LLC
• Merit Medical Systems Inc.
• Argon Medical Devices Inc.
• B Braun SE
• Simcere Pharmaceutical Group Limited
• pfm medical AG
• Redax SpA
• Wuhan YZY Biopharma Co. Ltd.
• Rocket Medical plc
• Genelux Corporation
• Gongwin Biopharm Holdings Co. Ltd.
• Ewimed GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 悪性胸水市場2029年：新たな機会を提供する国
• 悪性胸水市場2029年：新たな機会を提供するセグメント
• 悪性胸水市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Malignant pleural effusion (MPE) is the buildup of fluid in the pleural space caused by the presence of cancer cells, usually due to metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, resulting in increased vascular permeability and impaired lymphatic drainage.

The main treatment options for malignant pleural effusion include systemic therapy, therapeutic thoracentesis, thoracic drainage and pleurodesis, and the placement of an indwelling pleural catheter. Systemic therapy is a cancer treatment that circulates through the bloodstream to target and eliminate cancer cells throughout the body. Diagnosis is typically performed using methods such as pleural fluid cytology, immunohistochemical tests, imaging tests, pleural thoracentesis, pleuroscopy, and pleural biopsy. These treatments and diagnostic procedures are utilized by various end users, including hospitals, ambulatory clinics, and other healthcare facilities.

The malignant pleural effusion market research report is one of a series of new reports from The Business Research Company that provides malignant pleural effusion market statistics, including the malignant pleural effusion industry global market size, regional shares, competitors with the malignant pleural effusion market share, detailed malignant pleural effusion market segments, market trends, and opportunities, and any further data you may need to thrive in the malignant pleural effusion industry. This malignant pleural effusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing adoption of indwelling pleural catheters, a greater focus on palliative care, a rise in clinical trials, higher reimbursement rates, and the growing prevalence of metastatic malignancies.

The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, increased government support, a rising number of cancer survivors, growing demand for home-based care, and advancements in liquid biopsy. Key trends during this period include the integration of artificial intelligence in imaging tools, progress in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and the expansion of clinical trials for novel therapeutic agents.

The increasing number of lung cancer cases is expected to drive the growth of the malignant pleural effusion market. Lung cancer is a disease marked by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and disrupt normal lung function. The rise in lung cancer cases is largely due to smoking and tobacco use, as long-term exposure to harmful chemicals in cigarettes damages lung tissues, causes genetic mutations, and encourages the uncontrolled growth of cancerous cells, significantly raising the risk of developing the disease. Malignant pleural effusion signals advanced lung cancer progression by aiding the spread of tumors within the pleural cavity, which worsens respiratory function and leads to a poorer prognosis. For example, in January 2023, the American Cancer Society, a U.S.-based professional organization, reported that in 2022, there were an estimated 236,740 new cases of lung and bronchus cancer, with 130,180 estimated deaths. For 2023, new cases are expected to rise to 238,340, with deaths expected to decrease slightly to 127,070. This increase in lung cancer cases is driving the growth of the malignant pleural effusion market.

The improvement of healthcare infrastructure is anticipated to further fuel the growth of the malignant pleural effusion market. Healthcare infrastructure encompasses the physical, technological, and organizational elements required for delivering healthcare services, such as hospitals, clinics, medical equipment, IT systems, and healthcare personnel. The enhancement of healthcare infrastructure is driven by the need for better disease management and aims to improve accessibility, efficiency, and care quality. It supports better diagnosis, treatment, and management of malignant pleural effusion by granting access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately leading to improved patient outcomes. For instance, in May 2023, the American Health Care Association, a U.S.-based nonprofit organization, reported a 0.591% increase in the number of hospitals in the U.S., rising from 6,093 in the previous year to 6,129. This improvement in healthcare infrastructure is contributing to the growth of the malignant pleural effusion market.

Companies in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that designs drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly applied to conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For example, in September 2022, RS Oncology, LLC, a U.S.-based biotechnology company, initiated the MITOPE clinical trial, a first-in-human Phase 1/2 study conducted in the United Kingdom. This trial is evaluating RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.

Major players in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH.

North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant pleural effusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the malignant pleural effusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The malignant pleural effusion market consists of revenues earned by entities by providing services such as biopsy and cytology testing, chemotherapy and targeted therapy, and pleurodesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant pleural effusion market also includes sales of chest drainage systems, pleural access kits, and imaging-guided drainage equipment, and thoracentesis devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Malignant Pleural Effusion Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on malignant pleural effusion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for malignant pleural effusion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant pleural effusion market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Systemic Therapy; Therapeutic Thoracentesis; Thoracic Drainage And Pleurodesis; Indwelling Pleural Catheter
• 2) By Diagnosis: Pleural Fluid Cytology; Immunohistochemical Tests; Imaging Tests; Pleural Thoracentosis; Pleuroscopy; Pleural Biopsy
• 3) By End Users: Hospitals; Ambulatory Clinics; Other End Users
• Sub Segments:
• 1) By Systemic Therapy: Chemotherapy; Targeted Therapy; Immunotherapy
• 2) By Therapeutic Thoracentesis: Single-Time Thoracentesis; Repeated Thoracentesis
• 3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis; Mechanical Pleurodesis; Biological Pleurodesis
• 4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter; Non-Tunneled Pleural Catheter
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis International AG; Bristol-Myers Squibb Company; Gilead Sciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Malignant Pleural Effusion Market Characteristics

3. Malignant Pleural Effusion Market Trends And Strategies

4. Malignant Pleural Effusion Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Malignant Pleural Effusion Growth Analysis And Strategic Analysis Framework

• 5.1. Global Malignant Pleural Effusion PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Malignant Pleural Effusion Market Growth Rate Analysis
• 5.4. Global Malignant Pleural Effusion Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Malignant Pleural Effusion Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Malignant Pleural Effusion Total Addressable Market (TAM)

6. Malignant Pleural Effusion Market Segmentation

• 6.1. Global Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Therapy
• Therapeutic Thoracentesis
• Thoracic Drainage And Pleurodesis
• Indwelling Pleural Catheter
• 6.2. Global Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pleural Fluid Cytology
• Immunohistochemical Tests
• Imaging Tests
• Pleural Thoracentosis
• Pleuroscopy
• Pleural Biopsy
• 6.3. Global Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Clinics
• Other End Users
• 6.4. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Systemic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• 6.5. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Therapeutic Thoracentesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Time Thoracentesis
• Repeated Thoracentesis
• 6.6. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Thoracic Drainage And Pleurodesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemical Pleurodesis
• Mechanical Pleurodesis
• Biological Pleurodesis
• 6.7. Global Malignant Pleural Effusion Market, Sub-Segmentation Of Indwelling Pleural Catheter, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tunneled Pleural Catheter
• Non-Tunneled Pleural Catheter

7. Malignant Pleural Effusion Market Regional And Country Analysis

• 7.1. Global Malignant Pleural Effusion Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Malignant Pleural Effusion Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Malignant Pleural Effusion Market

• 8.1. Asia-Pacific Malignant Pleural Effusion Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Malignant Pleural Effusion Market

• 9.1. China Malignant Pleural Effusion Market Overview
• 9.2. China Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Malignant Pleural Effusion Market

• 10.1. India Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Malignant Pleural Effusion Market

• 11.1. Japan Malignant Pleural Effusion Market Overview
• 11.2. Japan Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Malignant Pleural Effusion Market

• 12.1. Australia Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Malignant Pleural Effusion Market

• 13.1. Indonesia Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Malignant Pleural Effusion Market

• 14.1. South Korea Malignant Pleural Effusion Market Overview
• 14.2. South Korea Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Malignant Pleural Effusion Market

• 15.1. Western Europe Malignant Pleural Effusion Market Overview
• 15.2. Western Europe Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Malignant Pleural Effusion Market

• 16.1. UK Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Malignant Pleural Effusion Market

• 17.1. Germany Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Malignant Pleural Effusion Market

• 18.1. France Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Malignant Pleural Effusion Market

• 19.1. Italy Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Malignant Pleural Effusion Market

• 20.1. Spain Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Malignant Pleural Effusion Market

• 21.1. Eastern Europe Malignant Pleural Effusion Market Overview
• 21.2. Eastern Europe Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Malignant Pleural Effusion Market

• 22.1. Russia Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Malignant Pleural Effusion Market

• 23.1. North America Malignant Pleural Effusion Market Overview
• 23.2. North America Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Malignant Pleural Effusion Market

• 24.1. USA Malignant Pleural Effusion Market Overview
• 24.2. USA Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Malignant Pleural Effusion Market

• 25.1. Canada Malignant Pleural Effusion Market Overview
• 25.2. Canada Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Malignant Pleural Effusion Market

• 26.1. South America Malignant Pleural Effusion Market Overview
• 26.2. South America Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Malignant Pleural Effusion Market

• 27.1. Brazil Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Malignant Pleural Effusion Market

• 28.1. Middle East Malignant Pleural Effusion Market Overview
• 28.2. Middle East Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Malignant Pleural Effusion Market

• 29.1. Africa Malignant Pleural Effusion Market Overview
• 29.2. Africa Malignant Pleural Effusion Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Malignant Pleural Effusion Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Malignant Pleural Effusion Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Malignant Pleural Effusion Market Competitive Landscape And Company Profiles

• 30.1. Malignant Pleural Effusion Market Competitive Landscape
• 30.2. Malignant Pleural Effusion Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Malignant Pleural Effusion Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Medline Industries LP
• 31.3. Becton Dickinson and Company
• 31.4. Cook Medical LLC
• 31.5. Merit Medical Systems Inc.
• 31.6. Argon Medical Devices Inc.
• 31.7. B Braun SE
• 31.8. Simcere Pharmaceutical Group Limited
• 31.9. pfm medical AG
• 31.10. Redax SpA
• 31.11. Wuhan YZY Biopharma Co. Ltd.
• 31.12. Rocket Medical plc
• 31.13. Genelux Corporation
• 31.14. Gongwin Biopharm Holdings Co. Ltd.
• 31.15. Ewimed GmbH

32. Global Malignant Pleural Effusion Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Malignant Pleural Effusion Market

34. Recent Developments In The Malignant Pleural Effusion Market

35. Malignant Pleural Effusion Market High Potential Countries, Segments and Strategies

• 35.1 Malignant Pleural Effusion Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Malignant Pleural Effusion Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Malignant Pleural Effusion Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer